

Resistance of topical Ophthalmic Drug Products in the novel *in vitro* **OphthalMimic** device

Prof. Dra. Taís Gratieri


Dr. Geisa N. Barbalho; Dr. Manuel Alves Falcão; Dr. Venâncio Amaral; Jonad
Contarato, Prof. Dr. Guilherme Martins Gelfuso; Prof. Dr. Marcílio Cunha Filho

Introduction

Biggest Challenges for Topical Ophthalmic Formulations

- Dynamic eye protection mechanisms affect penetration of topical ophthalmic formulations

↓ Drug penetration



Current Tests for Formulation Performance Assessment

↑ Time test


↑ Cost

🚫 Dynamic eye protection mechanisms


Concept

OphthalMimic can reproduce in vitro the dynamic eye protection mechanisms,


- Tear Flow and Drainage






- Blinking Movement



and incorporates a polymeric membrane that can evaluate the residence time capacity of formulations in the eye.




Incorporation of Reconstructed Human Cornea (SkinEthic HCE) into OphtalMimic Model




Results

Recovered moxifloxacin in HCE after the test in the Ophthalmimimic device



Conclusion



- The “Ophthalmimimic” device is a total *in vitro* method that suggests drainage of formulations more faithful to *in vivo* OCULAR DRAINAGE, *in vitro* CORNEAL RETENTION with simulated tear flow and a movable eyelid.
- Provide HIGH-THROUGHPUT SCREENING tools for evaluating ophthalmic drug product performance and may reduce the need for animal testing.

